236 related articles for article (PubMed ID: 22121002)
1. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle.
Albecka A; Belouzard S; Op de Beeck A; Descamps V; Goueslain L; Bertrand-Michel J; Tercé F; Duverlie G; Rouillé Y; Dubuisson J
Hepatology; 2012 Apr; 55(4):998-1007. PubMed ID: 22121002
[TBL] [Abstract][Full Text] [Related]
2. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus.
Molina S; Castet V; Fournier-Wirth C; Pichard-Garcia L; Avner R; Harats D; Roitelman J; Barbaras R; Graber P; Ghersa P; Smolarsky M; Funaro A; Malavasi F; Larrey D; Coste J; Fabre JM; Sa-Cunha A; Maurel P
J Hepatol; 2007 Mar; 46(3):411-9. PubMed ID: 17156886
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection.
Andréo U; Maillard P; Kalinina O; Walic M; Meurs E; Martinot M; Marcellin P; Budkowska A
Cell Microbiol; 2007 Oct; 9(10):2445-56. PubMed ID: 17517063
[TBL] [Abstract][Full Text] [Related]
4. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.
Syed GH; Tang H; Khan M; Hassanein T; Liu J; Siddiqui A
J Virol; 2014 Mar; 88(5):2519-29. PubMed ID: 24352472
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus.
Yamamoto S; Fukuhara T; Ono C; Uemura K; Kawachi Y; Shiokawa M; Mori H; Wada M; Shima R; Okamoto T; Hiraga N; Suzuki R; Chayama K; Wakita T; Matsuura Y
PLoS Pathog; 2016 May; 12(5):e1005610. PubMed ID: 27152966
[TBL] [Abstract][Full Text] [Related]
7. Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7.
Zhang F; Sodroski C; Cha H; Li Q; Liang TJ
Gastroenterology; 2017 Jan; 152(1):257-270.e7. PubMed ID: 27693511
[TBL] [Abstract][Full Text] [Related]
8. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells.
Frentzen A; Anggakusuma ; Gürlevik E; Hueging K; Knocke S; Ginkel C; Brown RJ; Heim M; Dill MT; Kröger A; Kalinke U; Kaderali L; Kuehnel F; Pietschmann T
Hepatology; 2014 Jan; 59(1):78-88. PubMed ID: 23873628
[TBL] [Abstract][Full Text] [Related]
9. Virology and cell biology of the hepatitis C virus life cycle: an update.
Dubuisson J; Cosset FL
J Hepatol; 2014 Nov; 61(1 Suppl):S3-S13. PubMed ID: 25443344
[TBL] [Abstract][Full Text] [Related]
10. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC
Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516
[TBL] [Abstract][Full Text] [Related]
11. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
12. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs.
Wunschmann S; Muller HM; Stipp CS; Hemler ME; Stapleton JT
J Infect Dis; 2006 Oct; 194(8):1058-67. PubMed ID: 16991080
[TBL] [Abstract][Full Text] [Related]
13. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles.
Tao W; Xu C; Ding Q; Li R; Xiang Y; Chung J; Zhong J
Virology; 2009 Dec; 395(1):67-76. PubMed ID: 19793603
[TBL] [Abstract][Full Text] [Related]
14. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape.
Zhao Y; Ren Y; Zhang X; Zhao P; Tao W; Zhong J; Li Q; Zhang XL
J Immunol; 2014 Jul; 193(2):783-96. PubMed ID: 24928988
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells.
Eyre NS; Phillips RJ; Bowden S; Yip E; Dewar B; Locarnini SA; Beard MR
J Hepatol; 2009 Sep; 51(3):446-57. PubMed ID: 19596477
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein.
Westhaus S; Bankwitz D; Ernst S; Rohrmann K; Wappler I; Agné C; Luchtefeld M; Schieffer B; Sarrazin C; Manns MP; Pietschmann T; Ciesek S; von Hahn T
Hepatology; 2013 May; 57(5):1716-24. PubMed ID: 23212706
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
Caron J; Pène V; Tolosa L; Villaret M; Luce E; Fourrier A; Heslan JM; Saheb S; Bruckert E; Gómez-Lechón MJ; Nguyen TH; Rosenberg AR; Weber A; Dubart-Kupperschmitt A
Stem Cell Res Ther; 2019 Jul; 10(1):221. PubMed ID: 31358055
[TBL] [Abstract][Full Text] [Related]
18. The specific infectivity of hepatitis C virus changes through its life cycle.
Keum SJ; Park SM; Park JH; Jung JH; Shin EJ; Jang SK
Virology; 2012 Nov; 433(2):462-70. PubMed ID: 22999258
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus is restricted at both entry and replication in mouse hepatocytes.
Park IW; Ndjomou J; Fan Y; Henao-Mejia J; He JJ
Biochem Biophys Res Commun; 2009 Sep; 387(3):489-93. PubMed ID: 19619513
[TBL] [Abstract][Full Text] [Related]
20. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes.
Podevin P; Carpentier A; Pène V; Aoudjehane L; Carrière M; Zaïdi S; Hernandez C; Calle V; Méritet JF; Scatton O; Dreux M; Cosset FL; Wakita T; Bartenschlager R; Demignot S; Conti F; Rosenberg AR; Calmus Y
Gastroenterology; 2010 Oct; 139(4):1355-64. PubMed ID: 20600021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
